North Chicago, Illinois, USA – May 21, 2026
Allergan Aesthetics, an AbbVie company and global leader in medical aesthetics, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Boey® (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adults. The recommendation represents a major advancement in aesthetic medicine and could position Boey as the first and only botulinum neurotoxin serotype E treatment approved in Europe for cosmetic use. The final European Commission decision is expected in the coming months and would apply across 30 European Economic Area markets if approved.
The positive CHMP opinion was supported by data from two pivotal global Phase III clinical trials evaluating the efficacy and safety of Boey in adults with moderate to severe glabellar lines, commonly known as frown lines. Researchers reported that the injectable treatment demonstrated rapid visible improvements beginning as early as eight hours after administration, with treatment effects lasting approximately two to three weeks. Industry analysts believe the product could introduce a differentiated option in the growing facial aesthetics market by targeting patients seeking shorter-duration injectable treatments with faster onset of action.
Phase III Trials Demonstrate Rapid Cosmetic Improvement
The positive regulatory recommendation was based on results from the pivotal M21-500 and M21-508 Phase III studies, which evaluated Boey’s efficacy and safety profile in adult patients with moderate to severe glabellar lines. According to Allergan Aesthetics, all primary and secondary clinical endpoints were successfully achieved across both studies, demonstrating statistically significant improvements in wrinkle appearance compared with placebo treatment.
Investigators highlighted Boey’s rapid onset of action as one of the therapy’s most important differentiating characteristics within the highly competitive botulinum toxin market. Clinical improvements were observed at the earliest assessment point of eight hours following administration, substantially faster than traditional neurotoxin products currently used in cosmetic medicine. Researchers additionally noted that treatment-emergent adverse events observed during the studies were generally comparable to placebo following both single-dose administration and repeated treatment cycles.
Advertisement
Medical aesthetics specialists believe faster-acting neurotoxin formulations could attract new patient populations interested in more flexible treatment scheduling and shorter-duration cosmetic procedures. Analysts also suggest that a reduced treatment duration may appeal to first-time injectable users who are hesitant to commit to longer-lasting facial aesthetic treatments.
Boey Could Introduce New Category in Aesthetic Injectables
Boey is based on botulinum neurotoxin serotype E, representing a different biologic mechanism from conventional botulinum toxin serotype A products widely used in cosmetic and therapeutic medicine today. Industry experts note that most currently marketed facial injectable neurotoxins rely on serotype A formulations with treatment effects typically lasting three to four months. Boey’s shorter treatment duration and rapid onset may create a new category within facial injectables focused on flexibility and temporary cosmetic enhancement.
Glabellar lines are vertical wrinkles that form between the eyebrows and are commonly associated with facial expressions such as frowning. In some individuals, these lines may contribute to appearances perceived as angry, tired, or stressed and can have measurable psychological and emotional impact. The global facial injectables market continues experiencing rapid growth as demand rises for minimally invasive aesthetic procedures and non-surgical cosmetic treatments worldwide.
Allergan Aesthetics confirmed that preparations are already underway for healthcare professional training and commercial launch activities in anticipation of a positive European Commission decision. Regulatory submissions for Boey are also currently under review in several additional international markets.
Allergan Expands Innovation in Medical Aesthetics
The CHMP recommendation further strengthens Allergan Aesthetics’ position within the global facial injectables industry, where the company remains one of the leading developers of neurotoxins, dermal fillers, body contouring technologies, and aesthetic devices. Analysts believe continued innovation in botulinum toxin science will remain a key driver of growth within the broader medical aesthetics market over the next decade.
Healthcare providers and aesthetic clinics increasingly seek injectable products that offer faster onset, predictable efficacy, improved patient convenience, and differentiated treatment flexibility. Industry experts expect newer biologic formulations such as Boey to contribute to expanding demand among younger consumers and first-time injectable patients globally.
As minimally invasive cosmetic procedures continue growing worldwide, the potential approval of Boey highlights the expanding role of biologic innovation and advanced neurotoxin science in shaping the future of facial aesthetics and personalized cosmetic medicine.
Source: Allergan Aesthetics press release
